Kymera Investor Day Presentation Deck

IRAKIMID Degrader KT-413 has Potential to be First Precision Medicine in DLBCL to Target a Genetically-defined Population (MYD88MT) Profound antitumor activity in preclinical models both in single agent and combination • Clinical strategy in place to enable accelerated approval: KYMERA Monotherapy MYD88MT DLBCL for most direct path to registration Other MYD88MT lymphomas of interest include PCNSL, WM Combinations With SOC agents in MYD88MT DLBCL to enable earlier line therapy ● ● ● ©2021 KYMERA THERAPEUTICS, INC. KYMERA R&D DAY - December 16th, 2021 PAGE 57

View entire presentation